Study S001455

A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00299871
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 542
Start: 2006-02
Primary completion: 2007-08
Lead sponsor: Sanofi
Conditions: Type 2 Diabetes
Interventions: DRUG:LIXISENATIDE (AVE0010)
Results posted: FALSE

Registered primary outcomes

HbA1c levels at baseline and endpoint (at 13 weeks). []

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0021613	Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Ratner RE, Diabetic medicine : a journal of the British Diabetic Association	2010	Randomized trial	PMID 20722676 DOI	registry reference RESULT:20722676